Gilead Persuades NICE To Overturn Zydelig Recommendation
This article was originally published in Scrip
Executive Summary
Gilead Sciences Inc. has managed to persuade NICE, the HTA body for England and Wales, to reverse an earlier recommendation that Zydelig (idelalisib) not be offered free of charge under the UK's NHS (National Health Service) for certain patients with chronic lymphocytic leukemia (CLL). The latest decision brings NICE in line with the Scottish Medicines Consortium, which approved Zydelig for use under NHS Scotland earlier this year.